The post Bitget Expands Pre-IPO Access as SpaceX Leads the Way appeared on BitcoinEthereumNews.com. Bitget has introduced a new product expanding early-stage marketThe post Bitget Expands Pre-IPO Access as SpaceX Leads the Way appeared on BitcoinEthereumNews.com. Bitget has introduced a new product expanding early-stage market

Bitget Expands Pre-IPO Access as SpaceX Leads the Way

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Bitget has introduced a new product expanding early-stage market access, with SpaceX selected as the first base asset in its IPO Prime offering. The move establishes a model that allows users to access private companies before they go public.

Bitget IPO Prime Introduces Pre-IPO Access

The IPO Prime model functions on a subscription basis, with approved users requesting for allocations based on their account status. Higher-tier users receive larger allocation limits. After the subscription phase ends, the allocated assets move into a structured OTC market within Bitget, allowing continuous trading and pricing.

The first product under this framework is preSPAX, which measures SpaceX’s economic performance following a possible SpaceX public listing. However, the asset does not represent equity ownership but mirrors potential upside tied to a qualifying event.

According to Bitget, the launch extends its Universal Exchange model into primary market access. This model combines multiple asset classes into a single platform, including crypto tokens, tokenized stocks, and other financial instruments.

PreSPAX Rollout Timeline Sets Airdrops Launch and Distribution Phases

The preSPAX rollout, according to an X post, includes multiple scheduled phases. Bitget will distribute two rounds of airdrops to eligible VIP users on April 13, 2026. The official token launch is set for April 21, 2026, with a commitment window running from April 18 to April 21.

Following the pledge phase, distribution will take place within a four-hour window on April 21. These timelines specify how users access and trade the asset from subscription to secondary circulation. In addition, Bitget stated that the product predicts only SpaceX’s economic performance and does not constitute a direct investment.

The company also clarified that SpaceX has not endorsed or authorized the offering. This follows a previous announcement where Bitget rolled out AI-driven trading accounts as part of a shift toward automation, strengthening its move into agent-native market structures.

Bitget Expands Broader Market Access Strategy

The IPO Prime launch follows a separate initiative introduced earlier, where Bitget rolled out a VIP Fast Track Program. That program focused on accelerating user progression through VIP tiers based on trading activity and account holdings.

The Fast Track Program gives users different incentives depending on user behavior. According to the press release, futures traders can earn up to 300 USDT in vouchers, while spot traders may receive fee rebates of up to 120 USDT. Users holding assets can access yield boosters reaching 7% in USDT.

Additionally, Bitget introduced a VIP dashboard that permits real-time tracking of user status. The dashboard specifies requirements for advancing to higher tiers and details benefits, such as reduced fees and access to unique bonuses.

Source: https://coingape.com/bitget-expands-pre-ipo-access-as-spacex-leads-the-way/

Market Opportunity
Notcoin Logo
Notcoin Price(NOT)
$0.0004636
$0.0004636$0.0004636
+2.11%
USD
Notcoin (NOT) Live Price Chart

SPACEX(PRE) Launchpad

SPACEX(PRE) LaunchpadSPACEX(PRE) Launchpad

Register for a chance to win a free lucky draw

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin is poised for a reversal if ETF demand returns or a ceasefire occurs, potentially crushing short sellers in a massive price squeeze.
Share
Coin Telegraph2026/04/04 19:58
Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Inertia is the invisible tax on modern industrial throughput. Every millisecond a robotic arm spends decelerating, or waiting for high-frequency vibrations to settle
Share
Techbullion2026/04/02 18:25

RealStocks Now Live

RealStocks Now LiveRealStocks Now Live

Trade real U.S. stock via regulated brokerage